Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YTS 109

Next Previous
Drug Profile

YTS 109

Alternative Names: YTS-109

Latest Information Update: 20 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator China Immunotech
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Autoimmune disorders; Haemolytic anaemia; Systemic lupus erythematosus

Most Recent Events

  • 19 Aug 2025 China Immunotech plans a phase I trial for Autoimmune diseases (Treatment-resistant) in China (Parenteral) in August 2025 (NCT07123519)
  • 08 Aug 2025 China Immunotech plans a phase I trial for Autoimmune disorders (Treatment-resistant) in China in August 2025 (Parenteral, Infusion) (NCT07104721)
  • 04 Aug 2025 China Immunotech (Beijing) Biotechnology plans a phase-I trial for Autoimmune disorders (Treatment-experienced, In adults) in China (Parenteral, infusion) (NCT07104721)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top